Elie Traer is an Oncology physician affiliated with Oregon Health & Science University. OpenAlex indexes 214 publications with 8,980 citations (h-index 35); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-9000Registry record last updated 27 Jun 2012.
Clinical trials
- Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
- JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Sponsor: OHSU Knight Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Syndax Pharmaceuticals, Inc.Program year20257 payments
- Stemline Therapeutics Inc.Program year20253 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology
2025 - Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Journal of Clinical Oncology
2024 - Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia
Cell Reports Medicine
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”